Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 7/20 | 0.38 |
| ▸ | DRD3 | P35462 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525433 | 0.94 | SMN1; SMN2 (0.42) | KMT2ADRD4DRD3MAPTKDM4E | |
| SCHEMBL5530846 | 0.90 | DRD2 (0.39) | KMT2ADRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL5525437 | 0.85 | DRD4 (0.37) | KMT2ADRD4DRD3MAPTDRD2 | |
| SCHEMBL5529068 | 0.85 | TP53 (0.37) | KMT2ADRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL5522872 | 0.84 | MAPT (0.43) | KMT2ADRD4DRD3MAPTKDM4E | |
| SCHEMBL5520783 | 0.84 | KDM4E (0.50) | KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL5530837 | 0.81 | MTOR (0.39) | DRD4MAPTALDH1A1DRD2 | |
| SCHEMBL5528273 | 0.79 | MAPT (0.39) | KMT2ADRD4DRD3MAPTKDM4E | |
| SCHEMBL5525377 | 0.78 | KDM4E (0.50) | KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL5530513 | 0.78 | MAPT (0.43) | DRD4DRD3MAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | KMT2A 2389/4885DRD4 3248/4885DRD3 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.